Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts - PubMed (original) (raw)

. 1998 Jul 1;58(13):2825-31.

Affiliations

PMID: 9661897

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts

J Baselga et al. Cancer Res. 1998.

Erratum in

Cancer Res 1999 Apr 15;59(8):2020

Abstract

Recombinant humanized anti-HER2 antibody, rhuMAb HER2, inhibits the growth of breast cancer cells overexpressing HER2 and has clinical activity. We explored in preclinical models its capacity to enhance the tumoricidal effects of paclitaxel and doxorubicin. In cultures of naturally HER2-overexpressing cancer cells, rhuMAb HER2 inhibited growth and enhanced the cytotoxic effects of paclitaxel. Treatment of well established BT-474 breast cancer xenografts overexpressing HER2 in athymic mice with rhuMAb HER2 resulted in a dose-dependent antitumor activity. In combination studies, treatment with paclitaxel and rhuMAb HER2 or doxorubicin and rhuMAb HER2 resulted in greater inhibition of growth than that observed with any agent alone. The combination of paclitaxel and rhuMAb HER2 resulted in the highest tumor growth inhibition and had a significantly superior complete tumor regression rate when compared with either paclitaxel or rhuMAb HER2 alone. Clinical trials that are built on these results are under way.

PubMed Disclaimer

Cited by

Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability.
Wilkinson EL, Sidaway JE, Cross MJ. Wilkinson EL, et al. Biol Open. 2016 Oct 15;5(10):1362-1370. doi: 10.1242/bio.020362. Biol Open. 2016. PMID: 27543060 Free PMC article.
Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion.
Chaganty BK, Lu Y, Qiu S, Somanchi SS, Lee DA, Fan Z. Chaganty BK, et al. Oncoimmunology. 2015 Oct 29;5(4):e1100790. doi: 10.1080/2162402X.2015.1100790. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141382 Free PMC article.
Antibody-dependent cytotoxicity mediated by chimeric monoclonal antibody Nd2 and experimental immunotherapy for pancreatic cancer.
Nishihara T, Sawada T, Yamamoto A, Yamashita Y, Ho JJ, Kim YS, Chung KH. Nishihara T, et al. Jpn J Cancer Res. 2000 Aug;91(8):817-24. doi: 10.1111/j.1349-7006.2000.tb01019.x. Jpn J Cancer Res. 2000. PMID: 10965023 Free PMC article.
Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.
Nagy P, Jenei A, Damjanovich S, Jovin TM, Szölôsi J. Nagy P, et al. Pathol Oncol Res. 1999;5(4):255-71. doi: 10.1053/paor.1999.0255. Pathol Oncol Res. 1999. PMID: 10607920 Review.
Crystalline monoclonal antibodies for subcutaneous delivery.
Yang MX, Shenoy B, Disttler M, Patel R, McGrath M, Pechenov S, Margolin AL. Yang MX, et al. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6934-9. doi: 10.1073/pnas.1131899100. Epub 2003 Jun 2. Proc Natl Acad Sci U S A. 2003. PMID: 12782786 Free PMC article.

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts - PubMed (original) (raw)